Edition:
United Kingdom

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

10.01USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$10.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
762,723
52-wk High
$13.41
52-wk Low
$4.36

Chart for

About

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor... (more)

Overall

Beta: 2.22
Market Cap(Mil.): $768.71
Shares Outstanding(Mil.): 112.22
Dividend: --
Yield (%): --

Financials

  IMGN.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -1.21 -- --
ROI: -63.15 1.56 14.38
ROE: -- 2.43 16.07

BRIEF-ImmunoGen Reports Q1 Loss Per Share $0.30

* IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2018 OPERATING RESULTS

04 May 2018

BRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine

* IMMUNOGEN ANNOUNCES SUCCESSFUL COMPLETION OF INTERIM ANALYSIS FOR FORWARD I PHASE 3 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT OVARIAN CANCER

26 Apr 2018

BRIEF-Immunogen Inc Files For Potential Mixed Shelf Offering‍​

* IMMUNOGEN INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING‍​ Source text (http://bit.ly/2DablVK) Further company coverage:

07 Mar 2018

BRIEF-Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11‍​

* IMMUNOGEN REPORTS PIPELINE PROGRESS AND 2017 OPERATING RESULTS

09 Feb 2018

BRIEF-Immunogen Says On Jan 8, Co Disclosed It Expects To Report That As Of Dec 31, 2017 It Had Cash And Cash Equivalents Of About $267.1 Mln

* IMMUNOGEN SAYS ON JAN 8, CO DISCLOSED IT EXPECTS TO REPORT THAT AS OF DEC 31, 2017 IT HAD CASH AND CASH EQUIVALENTS OF ABOUT $267.1 MILLION - SEC FILING Source text (http://bit.ly/2CRXR5Q) Further company coverage:

08 Jan 2018

BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies

* IMMUNOGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF IMGN632 FOR HEMATOLOGICAL MALIGNANCIES Source text for Eikon: Further company coverage:

04 Jan 2018

Earnings vs. Estimates